Atox Bio Email Format

BiotechnologyNorth Carolina, United States11-50 Employees

Atox Bio develops immunotherapy approaches for critically ill patients facing acute, life-threatening infections and rapid organ dysfunction. Its lead product, Reltecimod, is designed to modulate the immune response to support the resolution of organ failure in severe inflammatory conditions such as necrotizing soft tissue infections and sepsis. The company concentrates on late-stage clinical development to address significant unmet needs in acute care.

Reltecimod has progressed into phase 3 development, with enrollment completed in a pivotal NSTI study and a parallel phase 3, registrational study in sepsis-associated acute kidney injury. The company is headquartered in Durham, North Carolina, and holds regulatory designations including Orphan Drug status from the FDA and EMA and FDA Fast Track designation.

Get verified Atox Bio emails free

Company overview Employee directory